2024-05-03T08:46:45-04:00 2023-06-30 474306215 Mullins PC 7625 Wisconsin Avenue Bethesda MD 20814 990 2022-07-01 411688677 International Society for Pharmacoepidemiology INTE 529 14th St NW STE 1280 Washington DC 20045 James Vrac Executive Secre 3017186500 2024-05-01 true James Vrac XXX-XX-XXXX John Mullins P01429307 2027706371 2024-05-03 0 00 AAL1 IAL1 2022 2023-04-26 12:10:37Z Tobias Gerhard 2385393 false X www.pharmacoepi.org X 1989 NJ See Schedule O 20 20 0 125 0 0 0 787810 2328719 39712 56674 0 827522 2385393 5406 148360 0 0 0 0 886551 2805399 891957 2953759 -64435 -568366 4224312 3943001 723122 980587 3501190 2962414 See Schedule O false false 2531988 148360 2185377 Development and management of scientific forums: 1) convene an annual scientific forum (international conference on pharmacoepidemiology & therapeutic risk management - ICPE) where members of the discipline meet to network, present results of methodological investigations and studies in progress, discuss public health policy issues concerning pharmacoepidemiology, therapeutic risk management, and other related fields. 2) Convene regular regional and local meetings on scientific and public policy issues, which currently includes a mid-year conference in conjunction with meetings of the board of directors and scientific program committee; and an annual Asian conference (ACPE) partnered with local scientific and professional societies. 50676 The Societys communications program delivers: 1) a website with significant resources on the expanding science and practice of pharmacoepidemiology, and presents ISPEs goals and objectives to current/prospective members, and the general public; and 2) regular email updates to members on developments in pharmacoepidemiology, or about ISPE. 47170 Publications: 1) The Society provides a members-only subscription to Pharmacoepidemiology and Drug Safety, a leading scientific journal publishing definitive, peer-reviewed papers on the science and practice of pharmacoepidemiology; and 2) a Manuscript Initiative, which funds the development of resource documents focused on pharmacoepidemiology, pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management. 24555 Membership: With membership of over 2000 in more than 50 countries, the Society is the voice of pharmacoepidemiology, pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management. Members gain access to a rich and formidable network of like-minded individuals entirely focused on these issues, combined with career mentoring and professional development. 13185 The Societys education program delivers: 1) on-demand education sessions of a broad range of topics recorded at ISPE conferences and delivered online via the Education Center; and 2) a regular series of webinars based on current and breaking issues in pharmacoepidemiology presented by leading subject matter experts. 37740 2667574 true false false false false false false false false false true false false false false true true false false false true false true false false false false false false false false false false false false false false false false false false false false false false false false true 2 0 true 0 true false false false false false false false false false false false false X 20 20 false true false false true true true true true false false true true true true true true true true false X The Organization 3017186500 529 14th St NW Ste 1280 Washington DC 20045 X Andrea Margulis Director 1.00 0.00 X 0 0 0 Hongbo Yuan Director 1.00 0.00 X 0 0 0 Stanley Edlavitch Executive Director Emeritus 1.00 0.00 X 0 0 0 Ursula Kirchmayer Director 1.00 0.00 X 0 0 0 Daniel Prieto-Alhambra Director 1.00 0.00 X 0 0 0 Yoshiaki Uyama Director 1.00 0.00 X 0 0 0 Jennifer Lund Director 1.00 0.00 X 0 0 0 Stine Hasling Mogensen Director 1.00 0.00 X 0 0 0 Tomoko Kobayashi Director 1.00 0.00 X 0 0 0 Mette Norgaard Director 1.00 0.00 X 0 0 0 Jessica Franklin Director 1.00 0.00 X 0 0 0 Gillian Caughey Director 1.00 0.00 X 0 0 0 Shirley Wang Director 1.00 0.00 X 0 0 0 Montserrat Soriano Gabarro Director 1.00 0.00 X 0 0 0 Jeremy Rassen Director 1.00 0.00 X 0 0 0 Efe Eworuke Director 1.00 0.00 X 0 0 0 Lisa Pont President-Elect 2.00 0.00 X X 0 0 0 Vincent Lo Re Immediate Past President 2.00 0.00 X X 0 0 0 Caitlin Knox VP Finance-Elect 2.00 0.00 X X 0 0 0 Tobias Gerhard President 2.00 0.00 X X 0 0 0 James Vrac Executive Secretary 20.00 0.00 X 0 0 0 0 0 0 0 false false false Kellen Company 3200 Windy Hill Rd SE Ste 600W Atlanta GA 303398585 Management 496533 Bella Opr AS Center Blvd 5 Copenhagen S Copenhagen DA 2300 Venue rentalfood 1106202 Langelinie Pavillonen Langelinie 10 2100 Kobenhavn DA Venue rentalfood 241491 3 Membership Dues 900099 143342 143342 Conferences Meetings 900099 2185377 2185377 2328719 56674 56674 2385393 2328719 0 56674 X 148360 148360 496533 312310 184223 27643 14424 13219 108794 108794 8760 8760 521443 517114 4329 130719 125744 4975 275782 271209 4573 81522 74991 6531 710931 686547 24384 3488 3488 Social Programs 241491 241491 Bank and Credit Card Fees 76876 74498 2378 Special Projects 39670 27170 12500 Other 58478 34159 24319 23269 22003 1266 2953759 2667574 286185 0 409306 959090 124750 141166 947565 610295 107840 107840 2742691 2232450 4224312 3943001 43475 54047 679647 926540 723122 980587 X 3501190 2962414 3501190 2962414 4224312 3943001 -568366 29590 0 X false true X true false X 1860 1860 1911940 2290071 880724 787810 2328719 8199264 1911940 2290071 882584 787810 2328719 8201124 8201124 120597 47760 28586 32417 56674 286034 120597 47760 28586 32417 56674 286034 2032537 2337831 911170 820227 2385393 8487158 0.96630 0.96330 0.03000 0.04000 X 15390 15390 92450 92450 X 2414983 29590 29590 2385393 2385393 2953759 2953759 2953759 Footnote for uncertain tax position under FIN 48 (Part X) ISPE is exempt from the payment of income taxes on its exempt activities under Section 501 (c)(3) of the Internal Revenue Code.ISPE follows the Financial Accounting Standards Board Accounting Standards Codification, which provides guidance on accounting for uncertainty in income taxes recognized in ISPEs financial statements, if any. At year end, ISPE had no unrecognized tax benefits related to uncertain tax positions in its information return that would qualify for either recognition or disclosure in its financial statements. ISPEs policy would be to recognize interest and penalties on tax positions related to its unrecognized tax benefits in income tax expense in the financial statements. Through year end, there have been no matters that would have resulted in an accrual for interest and/or penalties.Generally, the tax years before 2019 are no longer subject to examination by federal, state, or local taxing authorities. true East Asia and the Pacific Program services Program 31786 Europe including Iceland and Greenland Program services Program 1906610 Sub-Saharan Africa Program services Program 31786 1970182 1970182 Asian Meeting Grants 140 19319 Annual Meeting Grants 94 112636 Mid-Year Meeting Grants 43 16405 false false false false false false Management duties delegation Part VI line 3 Effective January 2000, ISPE entered into an agreement with PAI Management Corporation, an association management company, to receive management and administrative services. This agreement may be terminated by either ISPE or the management company, upon proper notification, given a 90-day notification. As stated in the contract, any amendments to fees are approved through the annual ISPE budget.Kellen Company assumed the provision of management service to ISPE effective July 1, 2022. Members or stockholder classes and rights Part VI line 6 Members are individuals or organizations dedicated to pharmacoepidemiology research, education, and practice and its related description lines, and demonstrates and interest in promoting the growth of this field. All members have voting rights. Member election for additional members Part VI line 7a Every member has the right to elect members of the Organizations governing body. Governing body decisions Part VI line 7b The by-laws may be amended or repealed by action of the Board of Directors or by action of the general members. Form 990 governing body review Part VI line 11 Form 990 is prepared by an outside independent certified public accounting firm and submitted to senior ISPE management prior to distribution to ISPEs Board of Directors. A draft of Form 990 is sent to the Board of Directors with a final version available to the board after it is filed with the IRS. Conflict of interest policy compliance Part VI line 12c Conflict of interest discussed and resolved on a case by case basis as situations which could cause conflicts arise. CEO executive director top management comp Part VI line 15a Compensation of ISPEs Executive Secretary is paid by PAI Management Corporation through a management services contract (in lieu of full time professional staff) under which PAI provides a scope of management, technology and accounting services which is agreed upon and approved on a yearly basis by the Board of Directors. Other officer or key employee compensation Part VI line 15b ISPE operates under a management services contract with an outsourced management company in lieu of full time professional staff. Governing documents etc available to public Part VI line 19 The Organization makes it governing documents, conflict of interest policy, and financial statements available to the public upon request. List of other fees for services expenses Part IX line 11g Abstract Processing $28,027Other Professional Fees $80,767 General explanation attachment Mission Statement:The International Society for Pharmacoepidemiology (ISPE) is a non-profit international professional membership organization dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy, education, and advocacy for the field of pharmacoepidemiology, including pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management.